Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to MacroGenics
Related studies linked through entity extraction aliases.
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
- Status
- SUSPENDED
- Phase
- PHASE2
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study of MGC028 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Post-transplant Flotetuzumab for AML
- Status
- COMPLETED
- Phase
- PHASE1
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
- Status
- SUSPENDED
- Phase
- PHASE2
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Flotetuzumab Expanded Access Program
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE2
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
- Status
- TERMINATED
- Phase
- PHASE2